Showing 1 - 9 results of 9 for search 'Lionel D. Lewis', query time: 0.04s Refine Results
  1. 1
    Methotrexate encephalopathy: Two cases in adult cancer patients, who recovered with pathophysiologically based therapy

    Methotrexate encephalopathy: Two cases in adult cancer patients, who recovered with pathophysiologically based therapy by Shodeinde A Coker, David A Pastel, Melissa C Davis, Elizabeth M Bengtson, Camilo E Fadul, Lionel D Lewis

    Published 2017-05-01
    Get full text
    Article
  2. 2
    A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia

    A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia by Darcy B. Pooler, Dylan B. Ness, Alexey V. Danilov, Bridget M. Labrie, Tor D. Tosteson, Alan Eastman, Lionel D. Lewis, Frederick Lansigan

    Published 2022-11-01
    Get full text
    Article
  3. 3
    A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma

    A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma by Dylan B. Ness, Darcy B. Pooler, Steven Ades, Brian J. Highhouse, Bridget M. Labrie, Jie Zhou, Jiang Gui, Lionel D. Lewis, Marc S. Ernstoff

    Published 2023-06-01
    Get full text
    Article
  4. 4
    Tumor cell targeting by iron oxide nanoparticles is dominated by different factors in vitro versus in vivo.

    Tumor cell targeting by iron oxide nanoparticles is dominated by different factors in vitro versus in vivo. by Christian NDong, Jennifer A Tate, Warren C Kett, Jaya Batra, Eugene Demidenko, Lionel D Lewis, P Jack Hoopes, Tillman U Gerngross, Karl E Griswold

    Published 2015-01-01
    Get full text
    Article
  5. 5
    VISTA expression and patient selection for immune-based anticancer therapy

    VISTA expression and patient selection for immune-based anticancer therapy by Alexander S. Martin, Michael Molloy, Andrey Ugolkov, Reinhard W. von Roemeling, Randolph J. Noelle, Randolph J. Noelle, Lionel D. Lewis, Melissa Johnson, Laszlo Radvanyi, Robert E. Martell, Robert E. Martell

    Published 2023-02-01
    Get full text
    Article
  6. 6
    Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

    Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study by Asim Amin, Elizabeth R. Plimack, Marc S. Ernstoff, Lionel D. Lewis, Todd M. Bauer, David F. McDermott, Michael Carducci, Christian Kollmannsberger, Brian I. Rini, Daniel Y. C. Heng, Jennifer Knox, Martin H. Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J. Hammers

    Published 2019-03-01
    Get full text
    Article
  7. 7
    Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

    Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study by Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, Lionel D Lewis, Todd M Bauer, David F McDermott, Michael Carducci, Christian Kollmannsberger, Brian I Rini, Daniel Y C Heng, Jennifer Knox, Martin H Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J Hammers

    Published 2018-10-01
    Get full text
    Article
  8. 8
    Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights

    Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights by Randolph J. Noelle, Randolph J. Noelle, J. Louise Lines, Lionel D. Lewis, Robert E. Martell, Robert E. Martell, Thierry Guillaudeux, Sam W. Lee, Kathleen M. Mahoney, Kathleen M. Mahoney, Matthew D. Vesely, Jerome Boyd-Kirkup, Dhanya K. Nambiar, Andrew M. Scott, Andrew M. Scott

    Published 2023-09-01
    Get full text
    Article
  9. 9
    Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

    Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma by Pallawi Torka, Swetha Kambhampati Thiruvengadam, Lu Chen, Xiaoguang Wang, Canping Chen, Dan Vuong, Hanjun Qin, Alexandra Muir, Kirsten Orand, Ivana Borja, D. Lynne Smith, Alex F. Herrera, Stephen E. F. Spurgeon, Byung Park, Lionel D. Lewis, Francisco Hernandez-Ilizaliturri, Zheng Xia, Alexey V. Danilov

    Published 2023-01-01
    Get full text
    Article

Search Tools: